E-therapeutics Regulatory News (ETX)

e-Therapeutics plc

("e-Therapeutics" or the "Company")

Notification of Full Year Results Date

Oxford, UK - 6 April 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, will announce its full year results for the year ended 31 January 2017 on Wednesday, 19 April 2017.

-Ends-

For more information, please contact:

About e-Therapeutics plc

e-Therapeutics plc ("e-Therapeutics" or "the Company") is a drug discovery company with a unique and proprietary in silico discovery platform based on the application of network science to the modelling and analysis of cellular processes and leveraging public and proprietary chemical biology and "multi-omics" data.

The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property (IP) rights. The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology.

The platform is highly productive and, in new discovery projects, it consistently generates hits in phenotypic screens that have been progressed into potent, selective, novel drug-like molecules of multiple chemotypes.

Significant numbers of active molecules can be identified from screens of modest size, providing gains in both cost and time and enabling the use of more physiological assays thereby increasing the likelihood that candidates arising from the approach will translate into clinically efficacious drugs. It is based in Oxford, UK.

For more information, visit www.etherapeutics.co.uk.